Acquisition of Tetraphase Pharmaceuticals, Inc. Additional Information (Details) - USD ($) $ in Thousands		2 Months Ended	3 Months Ended		9 Months Ended
	Jul. 28, 2020	Sep. 30, 2020	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Business Acquisition [Line Items]
Inventory fair value step up adjustment					$ 1,186
Net product sales			$ 9,072	$ 5,706	22,468	$ 15,804
Amortization of intangible assets					$ 259
Tetraphase Pharmaceuticals, Inc.
Business Acquisition [Line Items]
Business acquisition, date of acquisition agreement	Jun. 24, 2020
Upfront cash for acquisition	$ 42,990
Future cash payments	16,000
Additional aggregate payments	16,000
Business acquisition, description					The holders of the CVRs are entitled to receive potential future cash payments of up to $16 million in the aggregate upon the achievement of certain net sales of XERAVA in the U.S. as follows: (i) $2.5 million if 2021 XERAVA U.S. net sales are at least $20 million; (ii) $4.5 million if XERAVA U.S. net sales are at least $35 million during any calendar year ending on or prior to December 31, 2024; and (iii) $9 million if XERAVA U.S. net sales are at least $55 million during any calendar year ending on or prior to December 31, 2024.
Estimated fair value of assets acquired	54,700
Estimated fair value of liabilities assumed	9,100
Inventory fair value step up adjustment	$ 3,300
Definite-lived intangible assets estimated useful life	10 years
Tetraphase Pharmaceuticals, Inc. | XERAVA
Business Acquisition [Line Items]
Net product sales		$ 1,900
Operating losses		6,400
Tetraphase Pharmaceuticals, Inc. | Cost of Product Sales
Business Acquisition [Line Items]
Inventory fair value step up adjustment		1,200
Tetraphase Pharmaceuticals, Inc. | Cost of Product Sales | XERAVA
Business Acquisition [Line Items]
Inventory fair value step up adjustment		1,200
Tetraphase Pharmaceuticals, Inc. | Selling, General and Administrative Expenses
Business Acquisition [Line Items]
Legal Fees			$ 300		$ 900
Tetraphase Pharmaceuticals, Inc. | Selling, General and Administrative Expenses | XERAVA
Business Acquisition [Line Items]
Amortization of intangible assets		$ 300
Agreement 1 | Tetraphase Pharmaceuticals, Inc.
Business Acquisition [Line Items]
Proceeds from businesses and interest in affiliates	$ 2,500
Net sales from related parties	20,000
Agreement 2 | Tetraphase Pharmaceuticals, Inc.
Business Acquisition [Line Items]
Proceeds from businesses and interest in affiliates	4,500
Net sales from related parties	35,000
Agreement 3 | Tetraphase Pharmaceuticals, Inc.
Business Acquisition [Line Items]
Proceeds from businesses and interest in affiliates	9,000
Net sales from related parties	$ 55,000